The Ketamine Clinic Boom: Safety Concerns in an Unregulated Market

The promise of rapid relief for depression and PTSD has fueled a massive boom in ketamine clinics across the United States. However, this explosive growth brings serious questions about patient safety. Behind the calming waiting rooms and glossy marketing campaigns, the industry operates with surprising blind spots and a troubling lack of federal oversight.

The Rapid Rise of Ketamine Treatment

Ketamine was approved by the Food and Drug Administration in 1970 as a surgical anesthetic. Over the last decade, doctors discovered that lower doses could rapidly reduce symptoms of severe depression, anxiety, and trauma. This discovery led to the current gold rush of private clinics.

It is crucial to understand the difference between FDA-approved treatments and off-label use. The FDA has only approved one ketamine-based drug for psychiatric use. That drug is Spravato, an esketamine nasal spray manufactured by Johnson & Johnson. Spravato comes with a strict Risk Evaluation and Mitigation Strategy program. This means patients must take the drug in a certified medical office and stay under observation for at least two hours to monitor for adverse reactions.

In contrast, the vast majority of private clinics offer intravenous (IV) ketamine infusions. Because ketamine is already an approved anesthetic, doctors can legally prescribe it “off-label” for mental health conditions. Off-label prescribing is common in medicine, but it means these IV treatments completely bypass the strict monitoring protocols required for Spravato.

Who is Running These Clinics?

When you walk into a psychiatric treatment center, you expect a mental health professional to oversee your care. In the ketamine industry, this is often not the case.

Because the drug is an anesthetic, many clinics are owned and operated by anesthesiologists, emergency room doctors, or nurse practitioners. While these professionals are experts at administering IVs and monitoring heart rates, they rarely have formal training in psychiatry. They might not know how to handle a patient experiencing a severe trauma response or a complex mental health crisis during a treatment session.

Furthermore, the business model is largely profit-driven. Entrepreneurs and venture capitalists are opening ketamine clinic franchises. They hire a medical director to write the prescriptions, but the primary goal is often to maximize the number of patients coming through the door.

Hidden Health Risks and Side Effects

Ketamine is a powerful dissociative drug. While many patients report life-changing benefits, the treatment carries real physical and psychological risks that are sometimes downplayed in marketing materials.

• Cardiovascular spikes: Ketamine can cause a sudden, temporary increase in blood pressure and heart rate. Clinics must actively monitor vital signs, but unregulated centers might lack the proper emergency equipment if a patient suffers a cardiac event.
• Psychological distress: The dissociative experience is often described as an “ego death” or a feeling of leaving the body. For a patient with severe trauma, this can trigger intense panic attacks if a trained therapist is not present to guide them.
• Bladder damage: Frequent, high-dose ketamine use is linked to a severe condition called ketamine cystitis. This causes painful urination, reduced bladder capacity, and sometimes irreversible damage.
• Addiction potential: Ketamine is a Schedule III controlled substance with a known history of recreational abuse. Without careful screening, clinics risk creating or feeding substance abuse disorders. The tragic overdose death of actor Matthew Perry in 2023 highlighted how easily medical ketamine access can spiral into fatal dependency.

The Telehealth Loophole: At-Home Ketamine

The safety concerns extend beyond physical clinics. During the COVID-19 pandemic, the federal government relaxed rules around prescribing controlled substances online. This sparked a boom in telehealth companies like Mindbloom, Joyous, and Wondermed.

These platforms ship ketamine lozenges directly to a patient’s home. Subscriptions can cost between $100 and $300 a month. While telehealth companies require a video consultation, patients are ultimately left to take a powerful dissociative drug in their living rooms without direct medical supervision.

Experts warn that at-home use drastically increases the risk of accidents, drug diversion, and unmonitored psychological distress. If a patient experiences a dangerous spike in blood pressure at home, no medical professional is there to intervene.

The High Cost of Unregulated Care

Patients desperate for relief often pay out of pocket for these treatments. Because IV ketamine is an off-label treatment for depression, major health insurance providers rarely cover the cost.

A single IV ketamine infusion typically costs between $400 and $1,000. A standard protocol requires six infusions over two to three weeks, bringing the initial cost to several thousand dollars. Patients then require periodic booster sessions to maintain their mental health improvements. This pricing structure creates an environment where clinics are financially motivated to prescribe ongoing treatments, even when long-term efficacy data is still lacking.

What Needs to Change

Medical associations are increasingly sounding the alarm. The American Psychiatric Association has published consensus statements calling for standardized protocols, but these guidelines are currently voluntary.

To protect patients, state and federal regulators need to step in. Proposed solutions include requiring clinics to have a board-certified psychiatrist on staff, mandating national registries to track adverse side effects, and enforcing stricter screening processes to prevent addiction. Until these safeguards are put in place, patients must navigate this booming industry with extreme caution.

Frequently Asked Questions

Is ketamine FDA approved for depression? Only one specific form of ketamine is FDA approved for treatment-resistant depression. That is Spravato, an esketamine nasal spray. IV ketamine infusions are used off-label for depression and do not have specific FDA approval for mental health treatment.

Are ketamine clinics covered by health insurance? Usually, no. Because IV infusions are off-label, patients must pay out of pocket, often spending $400 to $1,000 per session. Insurance plans may cover Spravato, provided the patient meets strict medical criteria.

What are the main risks of going to a ketamine clinic? Risks include sudden spikes in blood pressure, intense psychological distress during the infusion, potential bladder damage with frequent use, and the risk of developing a dependency on the drug.

Can anyone open a ketamine clinic? In many states, any licensed medical professional (such as a nurse practitioner or an anesthesiologist) can open a clinic. There is no federal requirement for these clinics to employ mental health professionals.